Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP262 in Chronic Inducible Urticaria (CALM-CIndU)
NCT06050928Phase 1Completed
- Sponsor
- Escient Pharmaceuticals
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of EP262 in chronic inducible urticaria (CIndU), sponsored by Escient Pharmaceuticals. Primary endpoint: Safety and tolerability of EP262 at 12 weeks. Started Aug 2023; status: completed.
02
Drugs
EP262
03
Conditions
chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on NCT06050928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06050928.